Worker’s Rights Questions Against Shein Mean The Forever 21-Shein Team-Up Could Make for a PR Headache

Fast fashion retailer Shein recently entered into a partnership with top retail brand Forever 21. However, the Forever 21-Shein team-up is raising eyebrows in the retail space, especially because Shein has previously faced accusations of human rights abuses and the usage toxic chemicals.

In the wake of major fashion mergers, what risks and ethical considerations arise, especially when sustainability is at stake?

Industry expert Lena Pinkston, a distinguished member of the Department of Retailing at the University of South Carolina, serving as both a clinical instructor and internship director, highlights the potential pitfalls of the recent Forever 21-Shein team-up.

“It’s just so many things abroad that Shein is getting away with, that they’re doing with no consequences. Whereas to bring that into our space could have really negative impacts on Forever 21. And in a way, it could tarnish their brand,” Pinkston said.

Article written by MarketScale.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More